PRTA logo

PRTAProthena Corporation plc

$8.79
$0.46
(4.97%)
Today
Closed $8.79
$0.17
(1.93%)
After Hours
Updated: 04:54 PM EDT
Reported EarningsMay 7
Mkt Cap$484.27M
Vol656,307.00
56

Bullish Sentiment

How do you feel about PRTA?

News
all
press releases
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Zacks
News Placeholder
More News
News Placeholder
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2026 and provided business highlights. In the quarter we...
Business Wire
News Placeholder
Prothena to Report First Quarter 2026 Financial Results on May 7
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire
News Placeholder
Prothena (NASDAQ:PRTA) Shares Up 5.9% - Time to Buy?
Prothena (NASDAQ:PRTA) Trading Up 5.9% - Here's What Happened...
MarketBeat
News Placeholder
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter...
Business Wire
News Placeholder
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts
Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) have earned a consensus rating of "Hold" from the eleven analysts that are covering the company, Marketbeat.com reports. Two...
MarketBeat
News Placeholder
Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving Average - Time to Sell?
Prothena (NASDAQ:PRTA) Share Price Passes Above 200 Day Moving Average - Here's Why...
MarketBeat
News Placeholder
Prothena Announces Leadership Team Updates
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire
News Placeholder
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
Zacks
News Placeholder
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Zacks
<
1
2
...
>

Advertisement|Remove ads.